Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + Paclitaxel in Advanced Oesophagogastric Carcinoma
NCT02406170Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Apr 2015
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in esophageal carcinoma, Gastric carcinoma (GC), sponsored by University of Amsterdam. Started Apr 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
esophageal carcinomaGastric carcinoma (GC)
Beyond the preview
Go deeper on NCT02406170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406170.